MONTREAL, Dec. 6, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP.TO) (OTC-BB:TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development announced today significant results from the study of Onternabez combined with Favipiravir against ARDS (acute respiratory distress syndrome), Sepsis, and COVID-19 through PREPAiRE, an AI (Artificial Intelligence) powered platform which purposely integrates target identification, validation, lead discovery optimization, drug synthesis, and preclinical testing. Leveraging the power of AI enables more answers and greater insights, faster.
Read more at newswire.caTetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir
Newswire.ca - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/amazon%20holiday%20delivery%20boxes%20by%20Cineberg%20via%20iStock.jpg)
